France's drug regulator clears SENS-601, an AAV gene therapy for GJB2-related hearing loss. Learn about this breakthrough in ...
Kali Therapeutics receives FDA clearance for KT501 tri-specific T-cell engager in rheumatoid arthritis. Clinical trials ahead ...
Gan & Lee Pharmaceuticals licenses bofanglutide European rights to Menarini Group for EUR 726 million. GLP-1 RA obesity ...
NMPA accepts Hansoh's HS-20093, a B7-H3 ADC for post-platinum small cell lung cancer. First ADC filing in indication. Learn ...
Revolution Medicines' Rasonque demonstrates 42% response rate in previously treated RAS-mutant NSCLC. Phase I/II data ...
AbbVie's etentamig achieves 60% progression risk reduction in Phase III CERVINO trial for relapsed-refractory multiple ...
Servier secures exclusive option to Luxna's XNA chemistry platform for antisense oligonucleotide neurological programs. Discover the collaboration details.
Hengrui's oral GLP-1 agonist HRS-7535 gains China regulatory acceptance for obesity and type 2 diabetes treatment. Latest ...
ARPA-H selects five teams for $125M in genetic medicine manufacturing. Discover how distributed production could revolutionize RNA-based treatments ...
Adicet Bio initiates Phase I/II trial of ADI-212, an allogeneic gamma delta CAR-T therapy for metastatic castration-resistant ...
NYM032, a domestically developed PSMA-targeted radioligand therapy, into pivotal Phase III testing for metastatic ...
Seoul National University researchers develop breakthrough prime editing platform for genomic DNA integration up to 6.5kb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results